120568-18-5

Basic information

• Product Name: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxaldehyde
• Synonyms: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxaldehyde;N-Trityl Losartan Carboxaldehyde;2-Butyl-4-chloro-1-[[2'-[1-(triphenylMethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]Methyl]-;N-Trityl Losartan-d4 Carboxaldehyde
• CAS NO: 120568-18-5
• Molecular Formula: C₄₁H₃₅ClN₆O
• Molecular Weight: 663.21
• Product Categories: Aromatics;Heterocycles;Intermediates
• Mol File: 120568-18-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Chloroform, Dichloromethane, Dimethyl Formamide, Ethyl Acetate, MEthanol
• CAS DataBase Reference: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxaldehyde(120568-18-5)
• EPA Substance Registry System: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxaldehyde(120568-18-5)

Safety Data

• Hazardous Substances Data: 120568-18-5(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Foam

Uses

Different sources of media describe the Uses of 120568-18-5 differently. You can refer to the following data:
1. An intermediate in the synthesis of the EXP 3174, a metabolite of Losartan
2. A labelled intermediate in the synthesis of the EXP 3174, a metabolite of Losartan.

Upstream product

• 83857-96-9 2-n-butyl-4-chloro-1H-imidazol-5-carboxaldehyde 
• 124750-51-2 N-(triephenylmethyl)-5-<4'-(bromomethyl)-biphenyl-2-yl>tetrazole 
• 905456-95-3 2-butyl-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carbaldehyde 
• 124751-00-4 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol 
• 894806-33-8 2-n-butyl-4-chloro-1-[4-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)benzyl]-1H-imidazole-5-carbaldehyde 
• 894806-32-7 (4-((2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl)phenyl)-boronic acid 
• 143945-72-6 N-trityl-5-(2-bromophenyl)tetrazole 
• 894806-34-9 2-butyl-4-chloro-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1H-imidazole-5-carbaldehyde 

Downstream Products

• 905456-95-3 2-butyl-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carbaldehyde 
• 124751-00-4 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol 

Relevant articles and documents

Monodentate Transient Directing Group Enabled Pd-Catalyzed Ortho-C-H Methoxylation and Chlorination of Benzaldehydes

We report Pd-catalyzed ortho-C-H methoxylation and chlorination of benzaldehydes by employing monodentate transient directing groups (TDGs) as an alternative strategy to bidentate TDGs. More importantly, a single crystal of benzaldehyde imine ortho-cyclopalladium intermediate was successfully obtained, and its structure was unambiguously determined by X-ray diffraction, which clearly showed that it was a binuclear palladium species bridged by a pyridone ligand. The utility of this approach was further demonstrated through the synthesis of key intermediates of natural products and drugs.

Dual-acting antihypertensive agents

The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

Angiotensin II receptor blocking agents

This disclosure describes novel imidazole compounds having the formula: STR1 wherein R 1 and R 6 are described in the specification which have activity as angiotensin II (AII) antagonists.